🇺🇸

Broad Market

· daily

Global High-Priority Regulatory Events — March 10, 2026

Across 50 filings centered on global high-priority events like insolvencies, SPACs, IPOs, and M&A, a dominant theme is financial distress in Indian infrastructure firms (e.g., Morarjee Textiles, VAS Infrastructure, Setubandhan) with ongoing CIRP and NCLT hearings signaling prolonged uncertainty. Biotech and SPAC sectors show mixed results: revenues grew in select cases like TWFG (+22% YoY) and Custom Truck (+7.9% YoY), but net losses widened sharply in biotechs (e.g., Cullinan +31% YoY, Rapport +42% YoY) due to R&D surges amid clinical investments. Period-over-period trends reveal revenue growth averaging +10-20% in resilient sectors like insurance (TWFG) and rentals (Custom Truck), contrasted by asset impairments and sales declines in energy/mining (Arq net loss to $52.6M, Uranium sales -59% YoY). Positive catalysts include SPAC mergers (IQM/RAAQ at $1.8B valuation, Horizon Quantum PIPE amendments) and strategic deals (Atlas Energy $840M Caterpillar pact), while insolvencies cluster around March 20 NCLT decisions. Capital allocation leans toward dilutions (e.g., Guided Therapeutics +5.6%) and cash raises over buybacks/dividends, with no major insider buys but executive changes (e.g., Playtika CFO resignation). Overall, portfolio-level patterns favor monitoring turnaround plays in SPACs/energy amid broad margin pressures (e.g., ACRES yield -150bps YoY). Actionable now: Avoid Indian insolvency names; eye SPAC closes and biotech cash runways.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 10, 2026

Overnight SEC filings reveal a diverse mix of 50 reports dominated by biotech and energy sector financings (e.g., Aclaris $39.8M, AN2 $40M), SPAC/M&A advancements (e.g., Alexander & Baldwin merger approved, IQM-RAAQ), and healthcare guidance reaffirmations amid risks (Elevance, Centene). Period-over-period trends show revenue growth in select areas like TWFG (+22% YoY), Custom Truck (+7.9% YoY), Arq (+10% YoY), but widespread margin compression (Arq gross margin -830 bps YoY, ACRES yield -155 bps), impairments (Arq $45M, Trailblazer assets -84% YoY), and losses widening (Bullish $785M net loss, BioNTech operating loss deepened). Capital allocation leans toward dilutions via ATMs/private placements (Trio $17.4M sold, 10+ shelf/S-1/F-1 filings) and buybacks (News Corp $1B program), with insider/activist activity limited but notable (Lululemon 13D/A nominations). Forward-looking catalysts cluster in Q2 2026 (Pershing Vantage close, Lipocine topline April), signaling portfolio-level caution on dilution-heavy small-caps versus stability in large-cap healthcare/insurance. Sector themes highlight biotech resilience via milestones despite cash burns, SPAC amendments easing paths to close, and industrial turnarounds via guidance (Arq FY26 $120-125M rev). Actionable now: Favor guidance-steady names, monitor merger votes.

24 high priority 26 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 09, 2026

Across 50 US SEC filings from March 9, 2026, dominant themes include a surge in M&A activity (e.g., Aureus Greenway merger, Lisata acquisition, CACI's $2.6B ARKA buy), biotech clinical and financing momentum (Relmada's 76% CR rate, Korro's $85M PIPE), and extensive leadership transitions (18+ appointments/resignations). Period-over-period trends show biotech cost efficiencies with 4/6 reporting R&D/OpEx cuts of 19-40% YoY (e.g., Boundless Bio -26% R&D Q4, Spruce -40% OpEx FY2025) amid narrowing net losses (-11% to -26% YoY), contrasted by energy firms raising capital amid production upticks (Battalion +1,200 bpd Jan vs Dec). Capital allocation leans toward equity/debt raises ($500M+ aggregate PIPEs/securitizations) and buybacks (Ingram Micro $50M), with positive sentiment in 60% of high-materiality filings (>8/10). Portfolio implications: Biotech overweight for catalysts like Phase 3 trials mid-2026; monitor energy leadership voids (Gulfport CEO exit). Forward catalysts cluster in Q2 2026 (merger closings, tender offers). Overall, actionable bullish tilt in growth sectors despite mixed leadership signals.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — March 09, 2026

Across 50 SEC filings for March 9, 2026, dominant themes include robust product revenue growth in biotech/pharma (e.g., ARS Pharma +888% YoY product rev to $72.2M) offset by surging expenses and widened losses (avg net loss expansion in 7/12 healthcare firms), SPAC extensions/mergers signaling prolonged deal hunts, and divergent energy results with dredge/oil producers outperforming producers (GLDD rev +16.5% YoY vs W&T -4.5%). Period-over-period trends show 14/25 10-Ks with revenue growth averaging +85% YoY in high-flyers like SharpLink (+666%) and BETA (+136%), but margin compression in 9/15 mixed sentiment firms (e.g., Cross Country operating loss to $84M from $17M) and SPAC cash burns. M&A activity surges with 5 deals (Aureus, Mission Produce, Xanadu), capital raises total >$100M (Bunker Hill C$33.7M, Battalion $15M), and positive guidance in Korn Ferry (Q4 rev $730-750M). Portfolio-level patterns flag healthcare turnaround potential amid commercialization ramps, energy FCF resilience despite price weakness, and SPAC dilution risks. Critical implications: Investors should prioritize firms with narrowing losses (Cumberland -55% YoY) and upcoming catalysts like closings/approvals, while monitoring SPAC liquidations.

31 high priority 19 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 09, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include surging M&A/takeover activity (e.g., Aureus Greenway-Autonomous Power merger, Mission Produce-Calavo acquisition), multiple Indian insolvencies (JCT Ltd, Unitech International, Jhaveri Credits), SPAC extensions amid delays, and mixed 10-K results with healthcare/biotech showing volatility. Period-over-period trends reveal revenue growth in outliers like Cumberland Pharma (+17.6% YoY to $44.5M), 908 Devices (+17.7% to $56.2M), SharpLink Gaming (+666% to $28.1M), and Tri-County Financial (+3.7% assets, +31% net income), contrasted by sharp declines in Cross Country Healthcare (-21.6% revenue, net loss to $95M), Cartesian Therapeutics (-93% revenue), and ARS Pharma (-5% total revenue despite product +). RBI data signals tight liquidity with net absorptions of ₹247k Cr (Mar 7) and ₹241k Cr (Mar 8), below CRR needs. Critical implications: M&A offers takeover premiums and catalysts, insolvencies flag distress selling opportunities, SPACs risk liquidation, while capital raises (Battalion $15M, Bunker Hill C$34M) bolster balance sheets. Portfolio-level: 7/15 10-Ks mixed sentiment with average revenue +18% in winners but losses widening 50-100% in losers; healthcare shows 5/10 margin pressures from impairments.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 09, 2026

Overnight SEC filings reveal mixed financial performances across sectors, with standout revenue growth in biotech/pharma (e.g., ARS Pharma product revenue +890% YoY to $72.2M, Cumberland Pharma +17.6% to $44.5M) offset by widening losses and expense surges in 7/15 key 10-Ks; energy firms like W&T Offshore (-4.5% revenue YoY) and Sphere 3D (-32.5%) show declines amid commodity pressures, while SPACs dominate with 8+ merger extensions/announcements. Period-over-period trends highlight revenue expansion averaging +50% YoY in high-growth niches (BETA Tech +136%, SharpLink +666%) but margin compression and net losses in 12/20 metric-rich filings (avg net loss expansion +150%). M&A activity surges with deals like Aureus Greenway/Autonomous Power and Mission Produce/Calavo, alongside financings totaling $100M+ (e.g., Bunker Hill C$33.8M). Capital allocation leans toward debt reduction (GLDD -15.6% long-term debt) and buybacks (News Corp $1B program, GLDD $12M repurchases), but insider activity is absent across filings. Forward-looking catalysts cluster in Q1-Q2 2026 (e.g., FAA certifications, drug approvals, closings), signaling portfolio rotation opportunities from underperformers like Cross Country (-21.6% revenue) to outperformers like Great Lakes Dredge (+16.5% revenue, +28.4% NI). Overall, bullish on select biotech/industrials amid SPAC consolidation, cautious on healthcare staffing and E&P.

31 high priority 19 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 08, 2026

The single filing in the Global High Priority Market Events stream features Ashok Leyland Limited's clarification under SEBI Regulation 30(11), deeming a March 6, 2026, Economic Times article and Chennai press conference non-material, with share price movements attributed solely to general market conditions. Neutral sentiment and low materiality (3/10) indicate no substantive impact or new catalysts, reinforcing the company's disclosure discipline without introducing volatility drivers. No period-over-period comparisons (YoY/QoQ revenue, margins) or financial ratios are present in the enriched data, suggesting stable underlying operations absent red flags. Absent insider trading activity, forward-looking guidance, capital allocation updates (dividends/buybacks), or transaction details further underscore this as a non-event. Key implication: reduces rumor-driven trading risks for ASHOKLEY (NSE)/500477 (BSE) investors. Portfolio-level pattern from 1/1 filings: emerging market firms proactively clarifying rumors to maintain transparency amid high-priority event scrutiny. Actionable takeaway: maintain positions, as no enriched data signals shifts in growth trends, management conviction, or scheduled events.

1 high priority 1 total filings
· daily

Global High-Priority Regulatory Events — March 07, 2026

The 16 filings reveal a dominant theme of financial distress across small-cap Indian companies, with 8 explicit insolvency-related updates (Hindware Home Innovation, Ushdev International, DiGiSPICE Technologies, Reliance Home Finance, Radhagobind Commercial, Tijaria Polypipes, Baron Infotech, JCT Limited) signaling widespread CIRP, liquidation, and creditor meetings amid no disclosed YoY/QoQ financial trends. Neutral-to-negative sentiment prevails (10/16 negative or neutral), with high materiality (avg 7.8/10) driven by NCLT proceedings, contrasting sparse positive regulatory resolutions like MRPL's rumor denial and Rathi's legal clearance. No period-over-period financial comparisons, insider trades (except promoter encumbrance), or capital allocation details are provided, limiting quantitative trends, but forward-looking catalysts cluster around March 2026 (voting results by Mar14, open offer Mar17-Apr2, CoC Mar9, NCLT Mar13). Portfolio-level pattern: Insolvency cluster in manufacturing/niche sectors (pipes, steel, fintech) suggests sector contagion risk, while open offers and mergers offer M&A alpha. Overall, bearish for exposed longs, opportunistic for distress plays.

16 high priority 16 total filings
· daily

US SEC Filings Daily Market Digest — March 06, 2026

Across 433 SEC filings dated March 6, 2026, for the period March 6, 2026, dominant themes include mixed 10-K results with revenue growth averaging +15% YoY in high-materiality filings (e.g., Chime +31%, Pattern Group +39%) offset by margin compression (-100 to -200 bps in 6/12 REITs/energy firms) and widened losses in biotech/REITs (e.g., Ares RE net loss doubled to $127M); M&A/SPAC activity surges with 15+ deals/announcements (e.g., Day One $2.5B acquisition, Quipt delisting post-arrangement); capital allocation favors dividends/buybacks (News Corp $1B program, MarketWise +25% dividend, 5 firms raised payouts); insider transitions neutral (e.g., Liberty CLO to advisor); delisting risks in 8 small caps (Traeger, Intensity regained but others flagged). Portfolio trends show REITs with NOI +12-21% but FFO drops (NewLake flat, Ares -82%), energy mixed (Granite production +28%, BP -12%), BDCs stable NAV/distributions. Forward guidance positive in 7/15 (MarketWise FY26 billings $300M, up from FY25 beat), bearish cuts in retail (Genesco FY27 sales flat). Implications: Opportunities in accretive M&A/guidance raises amid undervalued spin-offs; risks from delistings, covenant waivers (Nortech), impairments (Western Alliance $126M). Overall sentiment mixed (60% of 10-Ks), with action now on catalysts like March closings.

277 high priority 156 medium 433 total filings
· daily

Global High-Priority Regulatory Events — March 06, 2026

Across 303 filings dated March 6, 2026, focused on critical US SEC events like bankruptcies, takeovers, and regulatory actions, overarching themes include mixed 10-K performances with 12/20 named companies showing revenue growth (avg +15% YoY) offset by margin compression (avg -100bps in 8/15) and impairments, robust SPAC/IPO activity (e.g., Lendbuzz 83% revenue CAGR, APEX $112M IPO), and frequent delisting risks (7 small caps below $1/share). Positive catalysts dominate financings (Allarity $20M notes, Dave $175M convertibles) and M&A (Quipt takeover, HCL acquisition), while bearish signals cluster in insolvencies (Reliance fraud, Cyient JV liquidation) and energy REIT declines (NewLake assets -2.5% YoY). Portfolio-level trends reveal BDCs/REITs with NAV dips (avg -3%) amid stable dividends, insider pledges/terminations signaling caution (Camlin promoter pledge +0.94%), and forward guidance mixed (BP upstream flat 2026, Monroe pro forma NII +18% to 2030). Sector rotations favor fintech/AI IPOs over legacy energy (BP sales flat YoY), with capital returns steady (dividend hikes in 5/15). Actionable now: Buy dip in growth SPACs, avoid insolvency-linked names.

303 high priority 303 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 06, 2026

Overnight SEC filings (92 total) for March 5-6, 2026 reveal mixed FY2025 results across sectors, with average revenue growth of ~20% YoY in 25+ reporting companies (e.g., Chime +31%, Via +29%, Pattern +39%) offset by profitability challenges including widened losses (avg net loss expansion 15-30% in biotechs/REITs) and margin compression (-100bps avg in retail/energy). Energy/oil shows weakness (BP revenues flat, production -12% YoY; Granite Ridge NOI -22%), while fintech/SaaS outperforms on top-line (Guidewire +25%, MarketWise billings +13.5%) but faces expense pressures. REITs mixed with NOI growth in some (Unknown #10 +12.1%) but declines (Ares -2.1% same-store); BDCs/credit funds stable NAV/distributions. SPAC activity surges with IPOs (APEX $112M), extensions (Crown PropTech EGM Mar9), and combos (ReserveOne, Willow Lane). Capital allocation leans shareholder-friendly (MarketWise +25% dividend, resume $50M buyback; News Corp $1B repurchase), but debt raises proliferate (Waste Connections notes, Dave $175M conv notes). Key implications: Near-term catalysts from 10+ deal closings/meetings drive volatility; watch REIT/energy for impairments amid high debt trends.

59 high priority 33 medium 92 total filings
· daily

US Material Events SEC 8-K Filings — March 05, 2026

Across 84 SEC filings from March 5, 2026, dominant themes include widespread executive churn (25+ filings on appointments/departures, especially CFO/CAO roles like Sysco/McKesson swaps, Trulieve termination), robust M&A/divestiture activity (e.g., rare earth consolidation via USA Rare Earth/TMRC $73M deal, Six Flags $331M park sale), and financing enhancements (20+ credit amendments/extensions like RPM to 2031, Simon $5B rev revolver). Period-over-period trends show mixed revenue performance: growth in OptimizeRx FY2025 +19% YoY to $109.4M, Full House FY2025 +3.5% to $302.4M, Camp4 cash +71% to $109.5M, but declines in GoPro FY2025 -19% to $652M and hardware -21.5%; margins compressed in GoPro -290bps Q4 to 31.8%, flat EBITDA in Full House. Capital allocation leans shareholder-friendly with EPAM $300M ASR (remaining $452.5M program), OptimizeRx $10M buyback, AZZ board refresh for M&A/ESG. Critical implications: Positive for rare earths/tech consolidation amid supply chain risks, caution on media distress (Cumulus Ch11) and cannabis/consumer volatility; portfolio-level alpha in financing-secured growth names vs. restructuring risks.

84 high priority 84 total filings
· daily

US SEC Filings Daily Market Digest — March 05, 2026

Across 481 SEC filings for March 5, 2026, US markets show mixed corporate health with retail leaders like Burlington Stores (+9% FY sales, +2% comps) and BJ's (+4.6% FY sales) outperforming amid modest guidance (Burlington FY26 +8-10%), while consumer names like GoPro (-19% revenue) and Grove Collaborative (-15%) struggle with margin erosion. Biotech and pharma exhibit robust revenue surges (REGENXBIO +105% YoY, Lexicon +60%, Cryoport +12.4%) but persistent net losses and cash burn, offset by positive pipeline catalysts (e.g., Tenaya-Alnylam collab up to $1.13B milestones). Energy firms report production gains (Granite Ridge +27% YoY Q4, SandRidge +12% FY) and reserve growth (+9.5-15%), though revenues vary with prices; SPAC activity surges with Pasqal's $2B merger and multiple quantum deals. Portfolio trends reveal margin compression in 8/15 tech filings (avg -120bps despite +15-30% revenue), retail comp sales +1-5% avg in outperformers vs declines elsewhere, and capital returns via buybacks/dividends in 12 firms (e.g., EPAM $300M ASR, Kroger $7.5B repurchase). Insider patterns absent but management conviction via repurchases in Ranger (994k shares), Burlington ($117M Q4). Forward catalysts cluster in Q2 2026 (Northern Data acquisition, Pasqal Nasdaq listing, multiple earnings). Overall, actionable alpha in energy production plays and retail leaders amid quiet M&A uptick.

253 high priority 228 medium 481 total filings
· daily

Global High-Priority Regulatory Events — March 05, 2026

Across 285 filings from March 5, 2026, key themes include a surge in SPAC IPOs and mergers (e.g., Pasqal at $2B valuation, QuasarEdge, KPET), quantum computing catalysts (Pasqal, Xanadu), and distress in infrastructure/energy (multiple Jaiprakash defaults at ₹55k Cr debt, Cumulus Chapter 11, SKIL insolvency). Period-over-period trends show mixed revenue growth (avg +12% YoY in airlines/tech like LATAM +11%, CrowdStrike +22%; declines in media/energy like StubHub -1.4%, Stabilis -6.9%), margin compression in 15/50 quantified cos (avg -100bps, e.g., Full House EBITDA flat), and capex/debt rises amid M&A. Biotech/pharma mixed (Tenaya-Alnylam collab $1.13B milestones positive; Immatics loss swing), with positive leadership changes (SentinelOne CFO, Delta exec shuffles). Insider conviction low (no buys noted, sales rare), capital returns via buybacks (EPAM $300M ASR, Sysco reaffirmed). Portfolio-level: 40% mixed sentiment, quantum/SPAC bullish outliers, Indian insolvencies drag EM. Actionable: Monitor Q2-Q3 deal closes, CoC meetings.

285 high priority 285 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 05, 2026

Across 128 overnight SEC filings, retail and consumer sectors showed resilient top-line growth (e.g., Burlington +11% YoY sales, BJ's +5.5% Q4) but frequent margin compression (avg -100bps in 6/10 retailers) amid tariffs and costs, while biotech/pharma exhibited mixed results with strong product ramps (Liquidia +1031% revenue) offset by R&D spikes and losses. Quantum computing SPACs like Bleichroeder/Pasqal ($2B valuation, $600M proceeds) and Xanadu signal hot M&A in emerging tech, contrasting energy services' pricing pressures (Ranger Wireline -45% YoY). Capital allocation leaned shareholder-friendly with $10B+ in buybacks/dividends (Kroger $7.5B+$2B, EPAM $300M ASR, Ranger FCF >40% to repurchases/dividends). Guidance trends modest for 2026 (e.g., Burlington comps 1-3%, Kroger identical sales 1-2%) but positive outliers like Ciena raised FY26 to $5.9-6.3B (+28%). Portfolio-level: 45/128 positive sentiment, 60 mixed, 10 negative; YoY revenue growth avg +15% in winners but -20% in laggards like Silence (-99%). Key implication: Favor growth retail/biotech turnarounds with strong FCF, monitor quantum M&A redemptions.

65 high priority 63 medium 128 total filings
· daily

US Material Events SEC 8-K Filings — March 04, 2026

Across 77 US SEC filings from March 4, 2026, dominant themes include robust M&A/divestiture activity (12 deals totaling >$5B, e.g., SSR Mining $1.5B sale, Columbus McKinnon $2.7B acquisition), a surge in debt refinancings and equity offerings (25+ financings, e.g., $400M Alliant credit, $550M H2O offering) signaling liquidity needs amid mixed earnings, and high leadership churn (25+ changes, mostly neutral/positive appointments). Period-over-period trends show polarized performance: high-growth outliers like BillionToOne (+113% Q4 YoY revenue, +100% FY) and National Presto (+29.7% FY sales) contrast with decliners like Smith Micro (-20% Q4 YoY revenue) and Aquestive Therapeutics (FY revenue -3%), with average reported revenue growth ~+30% where disclosed but EBITDA/margins mixed (e.g., Babcock & Wilcox +53% Q4 EBITDA). Capital allocation leans toward debt reduction (e.g., Sabre redeemed $91.6M notes) and buybacks (Hess Midstream $60M repurchase), while one bankruptcy (Charles & Colvard) flags distress. Forward-looking catalysts cluster in Q2-Q3 2026 (M&A closes, earnings), with biotech/mining pivots to AI/critical minerals offering upside. Portfolio implications: overweight growth biotech/energy names, monitor small-cap financings for dilution risks, favor M&A active firms for synergies.

77 high priority 77 total filings
· daily

US SEC Filings Daily Market Digest — March 04, 2026

Across 433 SEC filings for March 4, 2026, mixed sentiment prevails with 60% of 10-Ks showing revenue growth (avg +12% YoY) but frequent margin compression (-120 bps avg in consumer/retail) and widened losses in 45% of cases, driven by SG&A surges (+25% avg YoY) and impairments. Consumer-facing firms like Kontoor Brands (+21% revenue YoY via acquisitions) and National Vision (+9% revenue, +56% adj op income) outperform, while energy producers like Gran Tierra (+32% production YoY but -23% EBITDA) and Xponential Fitness (flat SSS, -2% revenue) lag amid cost pressures. Capital allocation leans shareholder-friendly with buybacks/dividends in 25% of filings (e.g., Kontoor $25M remaining auth, News Corp $1B program), but dilution risks rise (US Energy 19% new shares). M&A/divestitures active (SSR Mining $1.5B sale, Ziff Davis asset sale), SPAC/de-SPAC momentum builds (Pelican, Haymaker), and financing abundant (Applied Digital $2.15B notes). Forward guidance cautious but positive in healthcare/tech (National Vision $107-133M adj op inc FY26). Portfolio trend: Rotate to margin-resilient growth (e.g., Cricut +26% op income) away from cyclical retail/energy.

215 high priority 218 medium 433 total filings
· daily

Global High-Priority Regulatory Events — March 04, 2026

Across 237 filings in the Global High Priority Market Events stream (US SEC focus, March 4, 2026), dominant themes include debt refinancings (e.g., Cooper-Standard $1.1B lower-cost notes), M&A/divestitures (SSR Mining $1.5B sale, Ziff Davis to Accenture), and distress signals like bankruptcies (Charles & Colvard Chapter 11) and insolvencies (TV Vision ₹294Cr petition). Period-over-period trends show mixed revenue growth (avg +8% YoY in reporting 10-Ks like National Vision +9%, Kontoor +21%, but declines in Xponential -2%, Sensus -34%) with widespread margin compression (e.g., 6/12 consumer firms -100-200bps avg due to SG&A rises) offset by cost savings in refinancings. Insider activity sparse but positive (Bondada promoter +0.003% stake), capital allocation leans to buybacks/dividends (Kontoor $25M remaining, Horizon $0.18 Q2 2026), while forward guidance highlights AI catalysts (Alnylam 2029 vesting at $500-800 stock price). Portfolio-level patterns flag energy/mining outperformance (Gran Tierra prod +38% YoY) vs retail weakness (Cracker Barrel rev -7.9% QoQ), with regulatory fines (BF Utilities ₹5.43L) and delistings (Vicarious NYSE suspension) amplifying volatility. Implications: Opportunistic buys in refinanced industrials, avoid distress names; monitor Q1 earnings for margin recovery.

237 high priority 237 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 04, 2026

Overnight SEC filings reveal a mixed but resilient US equity landscape, with precious metals ETFs (abrdn Gold, Silver, Platinum, Palladium, Precious Metals Basket) posting explosive YoY asset growth averaging 150-280% driven by metal price surges, contrasting margin compression and revenue declines in industrials (Eastern Co -190bps gross margin, HYSTER-YALE -12.5% revenue to net loss) and consumer (B&G Foods divestitures, Versant Media -5.3% revenue). BDCs and credit funds show portfolio expansion (e.g., 92-313 companies +43-109% commitments) but uniform yield declines to 8.5-9.2% from 9.5-10.2% amid rising leverage (5.7-6.3x), signaling caution in private credit. Tech outliers shine (Credo Technology +202% Q3 revenue to $407M, 68.5% margins), while biotech/pharma mixed with revenue volatility (Evolus +11.6%, Arcturus -46%). Governance filings dominate (50+ Nuveen DEF 14A for April 16 meetings, record dates Feb 9), neutral but highlighting virtual AGMs; SPACs (Pono, Cortigent) eye IPOs with dilution risks. Capital returns steady (buybacks/dividends in Copart, Superior Group), but restatements (ABVC revenue erased) and bankruptcies (Charles & Colvard Ch11) flag micro-cap distress. Portfolio trend: 40% positive sentiment in metals/resources, 30% mixed industrials/BDCs, implying rotation to commodities pre-market.

162 high priority 101 medium 263 total filings
· daily

US Material Events SEC 8-K Filings — March 03, 2026

Across 73 SEC filings dated March 3, 2026, dominant themes include a surge in M&A activity (10+ deals like Flowco's $200M Valiant acquisition, Esperion's $75M+ Enbumyst buy, Knightscope's Event Risk integration), extensive leadership transitions (25+ cases, mostly orderly retirements/appointments boosting expertise in healthcare/tech/energy), and robust capital markets engagement with $5B+ in debt issuances/refinancings (e.g., Leidos $1.4B notes, Vertiv $2.1B notes achieving IG status), share repurchases ($2B Pinterest ASR, $100M Trex), and equity facilities. Period-over-period trends show strong revenue growth in available data (Evolus FY2025 +12% YoY to $297M, Black Rock FY2025 +24.5% YoY to $200M, Byrna 84% CAGR to $118M), though mixed operating margins (Evolus non-GAAP loss widened, Black Rock op income -85% YoY). Positive sentiment prevails (45/73 filings), signaling sector resilience in healthcare (15 filings), energy (8), and consumer (6), with forward catalysts like Q2 2026 deal closes and H1 earnings. Portfolio-level patterns highlight undervalued buybacks amid M&A premiums (e.g., Select Medical 25% premium), but liquidity strains in biotechs (Karyopharm going concern). Implications: Bullish for M&A arbitrage and growth stocks, cautious on small-cap distress.

73 high priority 73 total filings